多瑞医药：王庆太和曹晓兵发出部分要约收购，拟收购1944万股，占总股本24.30%

Core Viewpoint - Duori Pharmaceutical announced a significant share transfer agreement involving the transfer of 23.68 million unrestricted circulating shares, representing 29.60% of the company's total share capital, from Tibet Jiakang Times Technology Development Co., Ltd. and its concerted actions to Wang Qingtai, Cui Zihao, and Cao Xiaobing [1] Group 1 - Tibet Jiakang and Zhoushan Qingchang plan to transfer a total of 23.68 million shares to Wang Qingtai and his concerted actions [1] - Wang Qingtai and Cao Xiaobing intend to further increase their stake in the listed company through a partial tender offer for an additional 19.44 million shares, which accounts for 24.30% of the total share capital [1]